Sun Pharma gains on launching INFUGEM in US

Mumbai : Sun Pharmaceutical Industries is currently trading at Rs. 465.90, up by 3.20 points or 0.69% from its previous closing of Rs. 462.70 on the BSE. The scrip opened at Rs. 469.90 and has touched a high and low of Rs. 469.90 and Rs. 464.75 respectively. So far 8700 shares were traded on the counter. The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 678.80 on 06-Sep-2018 and a 52 week low of Rs. 375.40 on 18-Jan-2019.

Last one week high and low of the scrip stood at Rs. 484.10 and Rs. 460.00 respectively. The current market cap of the company is Rs. 111017.23 crore. The promoters holding in the company stood at 54.38%, while Institutions and Non-Institutions held 32.53% and 13.09% respectively. Sun Pharmaceutical Industries has launched INFUGEM in the US for intravenous use. It is the first chemotherapy product that comes in a premixed, ready-to-infuse formulation, was approved by the US Food and Drug Administration (USFDA) in July 2018 in combination with other drugs for the treatment of breast, ovarian, non-small cell lung cancers, and as a single agent for the treatment of pancreatic cancer.

INFUGEM is an alcohol-free, clear, colorless, sterile solution of 10mg/mL gemcitabine in 0.9% sodium chloride that is supplied to pharmacists in ready-to-infuse bags as a Spike & Go package. It involves dose banding practice, whereby standardized doses of intravenous cytotoxic drugs are used for ranges of doses calculated for individual patients. Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

The post Sun Pharma gains on launching INFUGEM in US appeared first on Udaipur News | Udaipur Latest News | udaipur local news.

Leave a Reply

Your email address will not be published. Required fields are marked *